Alfasigma
Manufacturing · Italy · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Via Ragazzi Del '99 5, Bologna, Emilia-R...Phone Number
+39 516489511Website
www.alfasigma.comRevenue
$1.6 BillionIndustry
About Alfasigma
Alfasigma Org Chart
Is Alfasigma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Alfasigma has new funding data
Check out if Alfasigma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Alfasigma launches new products
Congratulate Masked Content for being promoted to Masked Content at Alfasigma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Alfasigma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Alfasigma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Alfasigma recently announced quarterly report
Click to see if Alfasigma had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Alfasigma as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Alfasigma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alfasigma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alfasigma.
Alfasigma Tech Stack
A closer look at the technologies used by Alfasigma
Most Recent Scoops
Alfasigma News & Media
Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease
BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology company, today announced a strategic partnership whereby Alfasigma will invest...Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold
MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its decision to voluntarily withdraw OCALIVA® (obeticholic acid) from the US market for the treatment of primary biliary cholangitis (PBC), a rare, progressive liver disease. This decision follows a request from the US Food and Drug Administration (FDA). In addition, FDA has placed a clinical hold on all Intercept clinical trials cIntercept Announces Data to be Presented at Digestive Disease Week 2025
Abstracts include a presidential plenary-selected Phase 2 study evaluating the combination of obeticholic acid and bezafibrate in PBC, along with 10 other abstracts Abstracts include a presidential plenary-selected Phase 2 study evaluating the combination of obeticholic acid and bezafibrate in PBC, along with 10 other abstractsForging New Paths: Alfasigma Group and Fangzhou Inc. Chart a Course for Internet Healthcare
SHANGHAI, Nov. 20, 2024 /PRNewswire/ -- On November 13th, a high-level delegation from the Alfasigma Group, led by Mr. Andriy Samoylovych, Chief Commercial Officer of Global Growth Markets, and Ms. Zhou Qin, General Manager of Alfasigma China, met with Dr. Xie Fangmin, Chairman and CEO of Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), at the Company's offices in Shanghai. The two companies discussed current trends in China's Internet healthcare sector, along with potential areas for
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alfasigma
Alfasigma S.p.A is an Italy-based multinational pharmaceutical company with a global presence in over 90 countries through distributors and subsidiaries. Founded in 2015, the company maintains in-house research and development capabilities alongside multiple production facilities. Alfasigma specializes in pharmaceutical products with a strong focus... Read More